Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biogen Idec, a biotechnology firm that manufactures, discovers, develops and commercializes therapies, has reported total revenues of $1.22bn for the fourth quarter ended 31 December 2010, compared to $1.13bn for the same period in 2009.
Subscribe to our email newsletter
For the fourth quarter of 2010, the company has generated net income of $271.75m, compared to $306m for the same period in 2009.
However, the income from operations was $355.19m, compared to $383.38m for the same period in 2009.
For the full year ended 31 December 2010, the company posted total revenues of $4.72bn, compared to $4.38bn for the same period in 2009.
Biogen Idec‘s net income was $898.57m for the full year of 2010, compared to $977.06m for the same period in 2009.
Income from operations was $1.25bn, compared to $1.3bn for the same period in 2009.
Biogen Idec CEO George Scangos said their solid 2010 performance reflects the strength of their core business.
"We will continue the company’s transformation in 2011, and we’re looking forward to several key pipeline milestones in the coming months," Scangos said.